• About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Login
  • Contact

o2h-ventures

  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Login
  • Contact

Don’t invest unless you’re prepared to lose all your money invested. This is a high risk investment. You could lose all the money you invest and are unlikely to be protected if something goes wrong. Take 2 mins to learn more

Oct 2022, o2h Ventures Fund Newsletter, KI EIS Closing, EISA events
Nov 1 2022

Firstly, welcome Rishi, whatever you and I think of his politics and experience, as an Anglo-Indian growing up in Cambridge in the 70’s and 80s, it is unbelievable that today we have an Anglo-Indian Prime Minister in the United Kingdom. His presence seems to be bringing calm to the markets. It is safe to assume that we are in a period of higher taxes to balance the books that we were under the leadership of Liz Truss.

Knowledge Intensive Fund Fully Invested

We have planned investments that will close in the 2-4 few weeks into:

Kuano: Kuano is an artificial intelligence company using quantum computing to create molecular design solutions. 

Qkine : Qkine manufactures high quality growth factors and cytokines for stem cell, organized and regenerative medicine applications.

PharmEnable : PharmEnable supports early drug discovery programs by providing a rapid, cost efficient, and effective platform to identify new hit candidates.

These investments will close to fully invest all our Knowledge Intensive Funds and thus we are seeking to raise a new fund which will close on November 15th 2023. 

EIS Certificate Updates

We are pleased to share that, since we have already invested more than 90% of the funds from the o2h human health KI Fund that closed on April 5th, April 2021, and October 30th, 2021, we will be issuing EIS5 Certificates to our investors in the coming days.  You will be able to download this from our portal at https://www.o2hventures.com We will send you an email as soon as we have received and uploaded this. 

New Investments for 2022/23

We are now working on due diligencing new investments and already in the pipeline we have pre-emption rights into companies such as Somaserve, Phoremost, Exonate, Alevin and Stingray which are strong candidates for further investment. 

Latest News from October

We attended Ready Steady Grow events organized by the Enterprise Investment Scheme Association (EISA) in Bristol, Manchester, and Belfast. Being on the panel and having the opportunity to interact, converse, and exchange knowledge about EIS and SEIS with other professionals in the field was amazing and a wonderful experience.

Enterprise Investment Scheme Association

KI Fund Close on November 15th 2022

Our HMRC approved the o2h human health knowledge-intensive EIS fund IV, is open for investment and the next close is coming up in 2 weeks time. The key benefits of investing in knowledge-intensive EIS funds are:

– Carry Back EIS Tax Relief: Carry back EIS tax relief to 2021/22, or the benefit of investing in this current year.

– Tax Relief: Can claim tax relief up to £2m per annum, provided that £1m is invested in the knowledge intensive companies.

– Simplified Paperwork: A single EIS5 Certificate for your investment rather than the typical 10–15 separate EIS3 certificates.

The fund aims to invest in early stage biotech companies that are involved in research, development, or innovation activities. 

Our onboarding procedure is quite quick—it won’t even take more than five to ten minutes. 

In case you run into trouble or want to learn more about the funds, we can set up a call and provide you with additional details. Just send us a short note to invest@o2h.com, and we’ll set up a time.

Connect with us
  • linkedin
  • twitter
  • instagram
  • facebook
  • youtube
o2h-ventures
related stories
  • Oct 2022, o2h Ventures Fund Newsletter, KI EIS Closing, EISA events 1 November, 2022
  • Aug-Sept 2022, o2h Ventures Fund Newsletter, fifty percent of our companies led by female and more portfolio updates 30 September, 2022
  • July 2022, o2h Ventures Fund Newsletter, Deals executed in Alevin Therapeutics, Neurofenix, Five Alarm Bio 1 August, 2022
o2h-ventures
The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years.
Useful Links
  • About Us
  • Blog
  • Documents Centre
  • Contact Us
  • Team
News
  • Oct 2022, o2h Ventures Fund Newsletter, KI EIS Closing, EISA events
  • Aug-Sept 2022, o2h Ventures Fund Newsletter, fifty percent of our companies led by female and more portfolio updates
  • July 2022, o2h Ventures Fund Newsletter, Deals executed in Alevin Therapeutics, Neurofenix, Five Alarm Bio
Connect with us
  • linkedin
  • twitter
  • instagram
  • facebook
© 2023 o2h ventures
  • Privacy Policy
  • Blog
  • Contact us
o2h ventures Limited is regulated and authorised by the Financial Conduct Authority (FRN 812245). Capital at risk, only suitable for high net worth and sophisticated investors

Risk Information

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

What are the key risks?

1 – You could lose all the money you invest

• If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.

2 – You are unlikely to be protected if something goes wrong

• Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)

• Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)

3 – You won’t get your money back quickly

• Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.

• The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.

• If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.

4 – Don’t put all your eggs in one basket

• Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.

• A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)

5 – The value of your investment can be reduced

• The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.

• These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)